» home » news » News releases    
 
 
05/01/11
Nanogea Profiled in Nature Methods Journal.
04/15/11
Nanogea Presents at 43rd Annual Oak Ridge Conference in Baltimore
03/31/10
Nanogea Annonces that It Can Detect Prostate-Specific Antigens (PSA) at Unprecedented Levels
 
 
Nanogea Presents at 43rd Annual Oak Ridge Conference in Baltimore

CULVER CITY, California, April 15, 2011 – Nanogea, a nano-biotechnology company focused on commercializing the industry’s most sensitive single molecular detection platform, was selected to present at the 43rd Annual Oak Ridge Conference in Baltimore. The Oak Ridge Conference is American Association for Clinical Chemistry’s annual forum for emerging clinical diagnostic technologies.

Nanogea’s presentation titled “Immunodetection of Individual Antigens Captured on an Antibody Microarray Platform by Force-Based Atomic Force Microscopy” profiled its core technology and described its success in detecting individual antigens in a sample. The basic process was previously profiled in a journal article titled: “Seeing and Counting” Individual Antigens Captured on a Microarrayed Spot with Force-Based Atomic Force Microscopy”, published in Analytical Chemistry in 2010. The study was conducted by Nanogea scientists Dhruvajyoti Roy and its Chief Scientific Officer Joon Won Park. The presentation at Oak Ridge was made by Lanna Cox, Nanogea’s Director of Business Development. An abstract of the presentation is shown below.

Dr. David Y Choi, Chief Business Officer of Nanogea, commented, "The implication of our study is that we can detect individual proteins with sensitivities that were considered impossible or difficult, in the range of 10^3 to 10^6 versus ELISA.” He added, “We can apply the basic technology for a wide range of applications such as diagnosing various CNS- or diabetes-related diseases. We can do this directly without sample preparation, without amplification or labeling. Other companies claim single molecule detection, we can do it at sensitivity levels that no one can.”

Abstract
Sensitive detection of disease biomarkers is a critical need in many aspects of modern biomedical research. In recent years, there has been increasing interest in early diagnosis of diseases, drug screening and monitoring of therapeutic treatments. For the ultrasensitive detection of low abundance biomarkers in blood great effort has been made by integrating different techniques or nanotechnologies to develop quantitative analytical tools. In the past decade, atomic force microscopy (AFM) has been widely used for direct quantification of biomolecular interactions at single-molecular level and it has evolved into a powerful tool in a wide range of disciplines such as materials and life sciences. Herein, the mapping capability of AFM has been employed for immunodetection of antigens captured on a spot microarrayed with the corresponding antibody and the number of the antigens was counted in a submicron area. This approach combined two key features: specificity determined by a probe antibody on the microarray format and a force-based AFM readout. The reliability and reproducibility of the approach were enhanced by employing a third generation dendron for the surface treatment. As a model system initially we focused on the sensitive detection of prostate specific antigens (PSAs) and the approach was extended for the detection of other biomarkers. The specific force between the captured antigen and the detection antibody was measured after cross-linking, and the mean unbinding force was calculated. The number of captured antigens within a selected area (120 nm x 120 nm) was counted, and our results indicate that the approach can be applicable to the quantitative analysis of the antigen in a sample and imply that it can be extended for the detection of various biomarkers in a sample of very low copy numbers as long as the size of the microarrayed spot is reduced.

About Nanogea
Nanogea, a nano-biotech company located in Westlake Village California, is focused on commercializing the industry’s most sensitive genomic and proteomic detection platform based on its innovative NanoCone™ chemistry and NanoCone Enabled Atomic Force Microscopy (NE-AFMTM) technology. The Company is utilizing its technology to push the genetic and protein detection limit to the single molecular level, thus greatly improving the sensitivity and accuracy of disease diagnosis, prognosis, treatment, and monitoring as well as drug discovery research. To learn more about its pioneering technology, visit www.nanogea.com.

Nanogea Corporation
5716 Corsa Avenue, Suite 201
Westlake Village, CA 91362.
Phone: (818) 889-0538, Fax: (818) 889-0816
E-mail: mlowrey@nanogea.com
Website: www.nanogea.com
 
© 2009 Nanogea, Inc. All rights reserved. Home | People | Technolgy | News | Contact
Web Design by fullestop